spiro<(3-aminomethylcyclohexane)-1,2'-dioxolane> | 7143-13-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: spiro<(3-aminomethylcyclohexane)-1,2'-dioxolane>
• 英文别名: 3-Aminomethylcyclohexanonethylenketal；C-(1,4-dioxa-spiro[4.5]dec-7-yl)-methylamine；1,4-Dioxaspiro[4.5]decan-7-ylmethanamine
• CAS: 7143-13-7
• 化学式: C₉H₁₇NO₂
• mdl: MFCD18483288
• 分子量: 171.239
• InChiKey: LQCUYCCICRWMAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  spiro<(3-aminomethylcyclohexane)-1,2'-dioxolane> 在 盐酸 、 lithium aluminium tetrahydride 、 potassium tert-butylate 、 sodium nitrite 作用下， 以 乙醇 、 叔丁醇 、 苯 为溶剂， 反应 21.0h， 生成 17-methyl-16-oxo-10-nor-14α-4,5-iminomorphinan
  参考文献：
  名称：

  亚二氢吲哚，吲哚和吲哚，二十一吗啉相关化合物的吲哚方法

  摘要：

  吲哚15的亚硝酸脱氨基用作制备吗啡类似物1b的新策略中的关键反应。

  DOI：

  10.1016/s0040-4039(00)85512-4
• 作为产物：
  描述：

  7-(nitromethyl)-1,4-dioxaspiro[4.5]decane 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 以71%的产率得到spiro<(3-aminomethylcyclohexane)-1,2'-dioxolane>
  参考文献：
  名称：

  亚二氢吲哚，吲哚和吲哚，二十一吗啉相关化合物的吲哚方法

  摘要：

  吲哚15的亚硝酸脱氨基用作制备吗啡类似物1b的新策略中的关键反应。

  DOI：

  10.1016/s0040-4039(00)85512-4

文献信息

• Indole as a tool in synthesis. Indolenine approach to 4,5-epoxy-10-normorphinans
  作者：Janos Sapi、Seloua Dridi、Jacqueline Laronze、Françoise Sigaut、Dominique Patigny、Jean-Yves Laronze、Jean Lévy、Loïc Toupet

  DOI：10.1016/0040-4020(96)00378-x

  日期：1996.6

  B-ring were synthesized using the “nitrous acid deamination” of indolenines as the key step. Thus, indolenines 13 and 15 were prepared by Fischer synthesis from the corresponding bicyclic ketolactams 6 and 12, respectively, and further transformed into the related hexahydrodibenzofurans. Ketolactam 6 was obtained from 3-nitromethylcyclohexanone using classical chemistry, whereas 12 was built up by fragmentation

  以吲哚烯酮的“亚硝酸脱氨基”为关键步骤合成了特征在于缺乏B环的吗啡骨架的4,5-环氧-10去甲吗啡喃2a和2b。因此，通过费歇尔合成法分别从相应的双环酮内酰胺6和12制备吲哚啉13和15，并将其进一步转化为相关的六氢二苯并呋喃。酮内酰胺6是使用传统化学方法从3-硝基甲基环己酮中获得的，而12通过使全氢pin庚酮断裂，然后进行分子内Diels-Alder环化作用来形成“环糊精”。虽然该过程导致了不自然的环连接（2b），但通过碱催化4,5-环氧17-甲基-9-氧代-10-nor-14α-吗啡喃21的差向异构化获得了自然构型（2a）。
• TRPV4 ANTAGONISTS
  申请人：GlaxoSmithKline Intellectual Property (No. 2) Limited

  公开号：EP2720697B1

  公开（公告）日：2016-07-20
• Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation
  作者：Yong-Jin Wu、Jason Guernon、Andrea McClure、Guanglin Luo、Ramkumar Rajamani、Alicia Ng、Amy Easton、Amy Newton、Clotilde Bourin、Dawn Parker、Kathleen Mosure、Omar Barnaby、Matthew G. Soars、Ronald J. Knox、Michele Matchett、Rick Pieschl、James Herrington、Ping Chen、D.V. Sivarao、Linda J. Bristow、Nicholas A. Meanwell、Joanne Bronson、Richard Olson、Lorin A. Thompson、Carolyn Dzierba

  DOI：10.1016/j.bmc.2017.08.012

  日期：2017.10

  Since zwitterionic benzenesulfonamide Na(v)1.7 inhibitors suffer from poor membrane permeability, we sought to eliminate this characteristic by replacing the basic moiety with non-basic bicyclic acetals and monocyclic ethers. These efforts led to the discovery of the non-zwitterionic aryl sulfonamide 49 as a selective Na(v)1.7 inhibitor with improved membrane permeability. Despite its moderate cellular activity, 49 exhibited robust efficacy in mouse models of neuropathic and inflammatory pain and modulated translational electromyogram measures associated with activation of nociceptive neurons. (C) 2017 Elsevier Ltd. All rights reserved.
• US8927585B2
  申请人：——

  公开号：US8927585B2

  公开（公告）日：2015-01-06
• [EN] TRPV4 ANTAGONISTS<br/>[FR] ANTAGONISTES DE TRPV4
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2012174340A1

  公开（公告）日：2012-12-20

  The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists. The TRPV4 antagonist may be administered alone or in conjunction with one or more other therapeutic agents, ego agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, vasopeptidase inhibitors, vasopressin receptor modulators, diuretics, digoxin, beta blocker, aldosterone antagonists, iontropes, NSAIDS, nitric oxide donors, calcium channel modulators, muscarinic antagonists, steroidal anti-inflammatory drugs, bronchodilators, anti-histamines, leukotriene antagonist, HMG-CoA reductase inhibitors, dual non-selective padrenoceptor and u1 -adrenoceptor antagonists, type-5 phosphodiesterase inhibitors, and renin inhibitors.